N

NERV: Minerva Neurosciences, Inc.

Stock

About

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Website
www.minervaneurosciences.com
Year Founded
2007
Employees
8
Sector
Health Care
HQ Location
Waltham, MA

Current Value

$1.51

1 Year Return

$1.00
-39.84%
Created with Highcharts 11.4.822 Apr20 May17 Jun15 Jul12 Aug9 Sep7 Oct4 Nov2 Dec30 Dec27 Jan24 Feb24 Mar$1$2$3$4

Key Details

Market Cap

$10.77M

P/E Ratio

8.1

1Y Stock Return

-39.13%

1Y Revenue Growth

-

Dividend Yield

0.00%

Price to Book

-0.4

Strategies that include NERV

Create your own
strategy with

NERV
Three dimensional double logo

Stock's related to NERV

The stocks that are correlated to NERV - Minerva Neurosciences, Inc. are DNLI, CVAC, GPCR, IPGP, LAW

Name
Correlation
Market Cap
Return % (1 Year)
Div Yield %
D
DNLIDenali Therapeutics, Inc.
37.17%$1.86B-32.65%0.00%
C
CVACCureVac NV
36.41%$637.03M-4.05%0.00%
G
GPCRStructure Therapeutics, Inc.
34.87%$935.49M-58.45%0.00%
I
IPGPIPG Photonics Corp.
31.81%$2.34B-36.86%0.00%
L
LAWCS Disco, Inc.
31.61%$232.48M-51.81%0.00%
A
ANABAnaptysBio, Inc.
30.73%$591.56M-9.44%0.00%
R
RCKTRocket Pharmaceuticals, Inc.
30.41%$592.86M-77.74%0.00%
A
AKROAkero Therapeutics, Inc.
30.30%$3.18B+74.10%0.00%
C
CLFDClearfield, Inc.
30.26%$382.26M-8.58%0.00%
G
GPROGoPro, Inc.
30.16%$86.27M-74.03%0.00%
A
ADSKAutodesk, Inc.
29.99%$54.77B+5.04%0.00%
H
HZOMarineMax, Inc.
29.57%$442.79M-34.45%0.00%
C
CMBMCambium Networks Corp.
29.57%$7.61M-93.75%0.00%
I
IVZInvesco Ltd.
29.55%$6.19B-16.33%6.27%
B
BNTXBioNTech SE
29.34%$22.08B+2.30%0.00%
E
ESTCElastic NV
29.19%$8.58B-15.79%0.00%
D
DHRDanaher Corp.
29.19%$141.59B-18.19%0.59%
P
PRLBProto Labs, Inc.
29.17%$806.24M-2.06%0.00%
P
PLRXPliant Therapeutics, Inc.
29.12%$80.22M-91.00%0.00%
N
NNOXNano-X Imaging Ltd.
29.11%$273.20M-57.04%0.00%

ETF's related to NERV

The ETFs that are correlated to NERV - Minerva Neurosciences, Inc. are XBI, IBB, CLOU, BBH, PBE

Name
Correlation
AUM
Expense Ratio
X
XBISPDR Biotech ETF
36.41%$5.06B0.35%
I
IBBiShares Biotechnology ETF
35.65%$5.70B0.45%
C
CLOUGlobal X Cloud Computing ETF
32.79%$315.74M0.68%
B
BBHVanEck Biotech ETF
32.34%$362.92M0.35%
P
PBEInvesco Biotechnology & Genome ETF
31.80%$229.13M0.58%
F
FBTTraded Fund III First Trust NYSE Arca Biotechnology Index Fund
30.37%$1.09B0.56%
W
WCLDWisdomTree Cloud Computing Fund
29.72%$398.68M0.45%
P
PRNTARK 3D Printing ETF
28.25%$73.55M0.66%
X
XSWSPDR S&P Software & Services ETF
28.00%$466.36M0.35%
P
PINKSimplify Health Care ETF
27.80%$141.74M0.5%
V
VHTVanguard Health Care ETF
27.61%$16.30B0.09%
G
GNOMGlobal X Genomics & Biotechnology ETF
27.58%$48.48M0.5%
R
ROBTTraded Fund VI First Trust Nasdaq Artificial Intelligence and Robotics ETF
27.25%$426.00M0.65%
F
FHLCFidelity MSCI Health Care Index ETF
26.95%$2.68B0.084%
B
BALTInnovator Defined Wealth Shield ETF
26.62%$1.37B0.69%
K
KRMAGlobal X Conscious Companies ETF
26.18%$597.93M0.43%
Q
QQQJTraded Fund Trust II Invesco NASDAQ Next Gen 100 ETF
26.17%$600.30M0.15%
X
XTiShares Exponential Technologies ETF
25.96%$3.00B0.46%
I
IWCiShares Micro Cap ETF
25.93%$809.63M0.6%
A
ARKGARK Genomic Revolution ETF
25.66%$987.53M0.75%

News

Yahoo

BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Tuesday reported a loss of $4.3 million in its fourth quarter.

Yahoo

BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024. Corporate Update As previously disclosed in the first quarter of 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New

Yahoo

BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Tuesday reported profit of $22.5 million in its third quarter.

Yahoo

BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024. Roluperidone NDA Update As announced in February 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Appli

Disclaimer

Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.

Zero expense ratio
index investing

Company

Resources

Popular ETFs

ETF Comparisons

© Double Finance, 2024

Double is a registered investment adviser with the US Securities and Exchange Commission (SEC). While such registration does not imply a certain level of skill, it does require us to follow federal regulations that protect you, the investor. By law, we must provide investment advice that is in the best interest of our client. Please refer to Double's Form CRS for important additional information.

The publicly available portions of the Platform (i.e., the sections of the Platform that are available to individuals who are not party to a Client Agreement - including double.finance) are provided for educational purposes only and are not intended to provide legal, tax, or financial planning advice. To the extent that any of the content published on publicly available portions of the Platform may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Nothing on the publicly available portions of the Platform should be construed as a solicitation or offer, or recommendation, to buy or sell any security. All charts, figures, and graphs on the publicly available websites are for illustrative purposes only. Before investing, you should consider whether any investment, investment strategy, security, other asset, or related transaction is appropriate for you based on your personal investment objectives, financial circumstances, and risk tolerance. You are also encouraged to consult your legal, tax, or investment professional regarding your specific situation. Registration does not imply a certain level of skill or training.

Investing involves risk. The value of your investment will fluctuate, and you may gain or lose money.

The contents of the Platform may contain forward-looking statements that are based on management's beliefs, assumptions, current expectations, estimates, and projections about the financial industry, the economy, or Global Predictions itself. Forward-looking statements are not guarantees of the underlying expected actions or future performance and future results may differ significantly from those anticipated by the forward-looking statements. Therefore, actual results and outcomes may materially differ from what may be expressed or forecasted in such forward-looking statements.

¹ Data as of July 2024.

² Availability of tax loss harvesting depends on portfolio diversity.

³ As of November 8, 2024. The optional Cash Sweep program takes the cash sitting in your brokerage account and moves it to an FDIC-insured interest-earning deposit account. The current yield is 1.0%, rates subject to change at any time. The cash sweep program is made available in coordination with Apex Clearing Corporation. Please read the Important Disclosures for more information.

⁴ This analysis calculator tool is for illustrative purposes only and is not financial advice. We do not guarantee the accuracy of the results or their relevance to your particular circumstances. This calculator uses hypothetical historical data and does not take into account the effect of taxes on a taxable account. Hypothetical historical data is no guarantee of future performance and this calculator is not intended to predict actual performance. The input of different time periods, amounts, and fees will vary calculator results. Average ETF fee is based on the AUM weighted average of US ETFs as of September 2024, see more information. Note that you can purchase ETFs through Double, which may incur additional fees.

Full pricing details along with an FAQ can be found here

Data displayed in charts and graphics above are for illustrative purposes only and do not reflect actual investment results and are not a guarantee of future results.

By using double.finance, you accept our and . Double is only available to US residents.

See Double Finance Form ADV Part IIA for additional information. Double does not guarantee that the results of its advice, recommendations, or the objectives of its direct index or cash management strategies will be achieved. We make no assurance that the investment process will consistently lead to successful investing. Before you invest, you should carefully review and consider your investment objectives as well as the risks, charges, and expenses of the underlying securities. There is at least a $1,000 account minimum required to participate in Double's strategies, although some strategies may have higher minimums.

Double does not provide tax, or legal advice. Double's website, brokerage, and advisory services are not intended for persons of any jurisdiction where Double is not authorized to do business. Tax savings will vary from client to client due to many factors including market conditions, tax characteristics of securities, client-imposed investment restrictions, client tax rate or status, and changes in tax regulations.

0% Expense Ratios with TLH

We offer over 50 indexes with zero expense ratios.

Registration will take about 10 seconds